New drug candidates being tested for erythropoietic protoporphyria (EPP) cannot yet be reliably compared with Scenesse (afamelanotide), the only approved treatment for adults with the disease, because their clinical trials are designed in very different ways, according to a new analysis. “Efficacy and safety of currently investigated treatments…